Evicenter
P&T meetings

Saroglitazar

Primary biliary cholangitis

Manufacturer
Zydus Therapeutics
Regulatory submission
NDA submitted by May 2026
Last updated
81 sources

Product information and disease descriptionProduct description

Product information

29 evidence topics · 27 sources

Average sales price and wholesale acquisition cost
Anticipated U.S. price, wholesale acquisition cost, and annual treatment-cost range

No evidence found.

Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions

Not applicable.